Nicotine dependence and neuropsychotic effects of varenicline
https://doi.org/10.30895/2312-7821-2018-6-1-19-22
Abstract
Varenicline is a partial agonist of nicotinic acetylcholine receptors for the therapy of nicotine addiction. The efficacy and safety of the use of varenicline in the treatment of nicotine dependence have been demonstrated in clinical trial EAGLES. These studies describe adverse reactions such us mental disorders: depression, suicidal thoughts, suicidal behavior. However, data on the increase in the incidence of these adverse reactions during longer treatment with varenicline was not obtained. In 2016, the FDA has been presented with information about the risk of development the following serious neuropsychiatric adverse reactions on the using of varenicline: depression, manic syndrome, psychosis, hallucinations, delusions, homicidal ideation, aggression, agitation, anxiety, panic, suicidal ideation, attempt of suicide. These adverse reactions were observed in patients with and without psychiatric disorders.
About the Authors
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products.
Russian Federation
Bukatina Tatyana M. Senior Analyst of the Research and Methodology Department of the DEMPS. PhD.
Russian Federation
Bukatina Tatyana M. Senior Analyst of the Research and Methodology Department of the DEMPS. PhD.
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products.
Russian Federation
Russian Federation
Kazakov Alexander S. Head of the Research and Methodology Department of the DEMPS. PhD.
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products.
Russian Federation
Russian Federation
Alyautdin Renad N. Head of the DEMPS. MD, PhS, DSc, prof.
T. V. Romanova
Scientific Centre for Expert Evaluation of Medicinal Products.
Russian Federation
Russian Federation
Romanova Tatyana V. Analyst of the 1st category of the Department of Science and Analysis Department of the DEMPS.
I. I. Snegireva
Scientific Centre for Expert Evaluation of Medicinal Products.
Russian Federation
Russian Federation
Snegireva Irina I. Head of the Department for Evaluation of MIBPs-associated Adverse Effects. PhD.
References
1. Crawford P, Cieslak D. Varenicline for Smoking Cessation. Am. Fam. Physician 2017; 96(5): online.
2. Hayato A, Shinji O, Akio N, Kousuke O, Shigeru O, Naoko I, et al. Assessment of the Risk of Suicide-Related Events Induced by Concomitant Use of Antidepressants in Cases of Smoking Cessation Treatment with Varenicline and Assessment of Latent Risk by the Use of Varenicline. PLoS One 2016; 11(9): 1-12.
3. Zhuravleva MV, Kukes VG, Prokofiev AB, et al. Efficacy and safety of medicines: the value and opportunities of clinical pharmacology. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2015; (2): 20-24. (In Russ.).
4. Molero Y, Lichtenstein P, Zetterqvist J, et al. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ 2015; 350.
5. Tobacco Fact sheet. WHO; [Internet]. 2017 (cited 10 May 2017). Available from: http://www.who.int/mediacentre/factsheets/fs339/en.
6. Neil M Davies, Taylor G, Amy E Taylor, et al. What are the effects of varenicline compared with nicotine replacement therapy on long-term smoking cessation and clinically important outcomes? Protocol for a prospective cohort study. BMJ Open 2015; 5(11): e009665.
7. Rodionov AV. New Opportunities of Treatment of Nicotine Addiction in Patients with Cardiovascular Disease: Efficacy and Safety of Varenicline.Effective pharmacotherapy. Cardiology and Angiology 2016; 42(2): 2-5. (In Russ.).
8. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 2005; 48(10): 3474-3477.
9. FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban (1 July 2009) [Internet]. 2017 (cited 10 May 2017). Available from: https://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm170906.htm.
10. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a doubleblind, randomised, placebo-controlled clinical trial. The Lancet 2016; 387(10037): 2507-2520.
11. Drug Safety Labeling Changes (SLC). CHANTIX (VARENICLINE TARTRATE) (16 December 2016) [Internet]. 2017 (cited 10 May 2017). Available from: https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=388.
12. Avdeev SN, Avedisova AS, Avetisov SE, et al. Federal guidance on the use of drugs (formulary system). Ser. Library of the Russian national Congress «Man and medicine». Release of the XVIII (18th Edition, revised and enlarged). Moscow, 2017. (In Russ.).
13. Romanov BK, Glagolev SV, Polivanov VA, Leonova MV. Monitoring the safety of medicines. Safety and Risk of Pharmacotherapy 2014; 3(4): 11-14. (In Russ.).
14. Romanov BK, Toropova IА, Kolesnikova EYu. Medication errors. Safety and Risk of Pharmacotherapy 2014; 2: 28-30. (In Russ.).
Review
For citations:
Bukatina T.M., Kazakov A.S., Alyautdin R.N., Romanova T.V., Snegireva I.I. Nicotine dependence and neuropsychotic effects of varenicline. Safety and Risk of Pharmacotherapy. 2018;6(1):19-22. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-1-19-22
Views:
1483
Email this article 